The individual research projects comprising this SPORE application require the procurement, processing, and analysis of histopathological material from patients with ovarian cancer and benign ovarian diseases. The research projects have needs for frozen and formalin-fixed, paraffin-embedded samples of tumor and normal tissue. The proposed Pathology Core augments the already established M. D. Anderson Cancer Center Gynecological Tumor Bank and the PSO sponsored M. D. Anderson Cancer Center Centralized Tissue Repository with supporting database and intranet access. The Core provides for tissue acquisition by experienced gynecological pathologists to assure high-quality tissues for the investigators participating in this SPORE as well as investigators of other SPOREs. The goal of the Pathology Core is to provide frozen tissue, paraffin-embedded tissue, and histopathological expertise related to the specific needs of the research projects comprising this SPORE proposal. To achieve this goal, the Pathology Core proposes the following Specific Aims, which remain unchanged since the previous renewal.
Aim 1 will maintain a frozen and paraffin-embedded tissue repository of ovarian cancer, benign ovarian processes, and normal ovary. The primary tissue source will be operative and biopsy specimens submitted to the Dept of Pathology at M. D. Anderson Cancer Center.
Aim 2 will provide pathological review for all clinical specimens utilized in the SPORE projects and to provide histopathological technical services as necessary. Such technical services include immunohistochemistry, in situ hybridization, creation of specific tissue microarray slides, pathological evaluation of mouse tumors, and microdissection of tissue sections.
Aim 3 will establish a blood/urine/ascites fluid repository from patients undergoing surgery for ovarian cancer and benign ovarian processes. These fluids will provide the resources for the systemic testing of putative prognostic and diagnostic markers derived from tissue-based expression array and CGH experiments.
Aim 4 will create and maintain a relational SPORE Database for all samples collected by the Pathology Core. This SPORE Database will provide for a virtual tissue repository that can be electronically shared with all SPORE investigators.
The Pathology Core collaborates with all SPORE project investigators to aid in translational research for ovarian cancer. The Core provides ovarian cancer tissues, ovarian cancer slides, and technical expertise in the microscopic interpretation of experiments utilizing immunohistochemistry.
|Umamaheswaran, Sujanitha; Dasari, Santosh K; Yang, Peiying et al. (2018) Stress, inflammation, and eicosanoids: an emerging perspective. Cancer Metastasis Rev 37:203-211|
|Wang, Jue; Zhao, Wei; Guo, Huifang et al. (2018) AKT isoform-specific expression and activation across cancer lineages. BMC Cancer 18:742|
|Huang, Yan; Hu, Wei; Huang, Jie et al. (2018) Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther 17:464-473|
|Yang, Hailing; Mao, Weiqun; Rodriguez-Aguayo, Cristian et al. (2018) Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res 24:5072-5084|
|Rhyasen, Garrett W; Yao, Yi; Zhang, Jingwen et al. (2018) BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. PLoS One 13:e0200826|
|Chen, Jian; Zaidi, Sobia; Rao, Shuyun et al. (2018) Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-? Pathway. Gastroenterology 154:195-210|
|Sun, Chaoyang; Yin, Jun; Fang, Yong et al. (2018) BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell 33:401-416.e8|
|Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15|
|Jung, Youn-Sang; Wang, Wenqi; Jun, Sohee et al. (2018) Deregulation of CRAD-controlled cytoskeleton initiates mucinous colorectal cancer via ?-catenin. Nat Cell Biol 20:1303-1314|
|Jung, Youn-Sang; Jun, Sohee; Kim, Moon Jong et al. (2018) TMEM9 promotes intestinal tumorigenesis through vacuolar-ATPase-activated Wnt/?-catenin signalling. Nat Cell Biol 20:1421-1433|
Showing the most recent 10 out of 648 publications